Gog-3031- A Phase 3, Randomized, Double-Blind, Multicenter Study Of Dostarlimab (Tsr-042) Plus Carboplatin-Paclitaxel Versus Placebo Plus Carboplatin-Paclitaxel In Patients With Recurrent Or Primary Advanced Endometrial Cancer (Ruby)
Posted Date: Oct 26, 2020
- Investigator: Caroline Billingsley
- Specialties: Cancer, Gynecology, Oncology
- Type of Study: Drug
The purpose of this study is to determine the rate of progression free survival in Dostarlimab plus Carboplatin-paclitaxel compared to carboplatin-paclitaxel plus a placebo in patients with Recurrent or Primary Advanced Endometrial Cancer
Criteria:
To Be Eligible: Histologically Or Cytologically Proven Endometrial Cancer With Recurrent Or Advanced Disease, Ecog 0-1, Adequate Organ Function, No Neo-Adjuvant/Adjuvant Systemic Chemotherapy For Primary Stage Iii Or Iv Disease, No Other Malignancy Within
Keywords:
Endometrial Cancer, Uterine Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com